Stock Analysis on Net

CVS Health Corp. (NYSE:CVS)

Income Statement 
Quarterly Data

The income statement presents information on the financial results of a company business activities over a period of time. The income statement communicates how much revenue the company generated during a period and what cost it incurred in connection with generating that revenue.

CVS Health Corp., consolidated income statement (quarterly data)

US$ in millions

Microsoft Excel
3 months ended: Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Products 57,669 61,911 59,674 56,212 53,724 65,154 61,298 60,539 58,147 59,657 57,643 56,794 52,522 53,973 51,853 50,525 47,387 49,592 47,738 46,355 47,003
Premiums 32,820 30,913 30,925 30,667 30,391 25,075 24,657 25,108 24,352 21,436 21,003 21,260 21,631 19,205 18,984 18,983 18,960 17,615 17,182 16,927 17,640
Services 3,579 4,131 4,279 3,961 3,868 3,316 3,532 3,000 2,445 2,430 2,312 2,436 2,505 3,059 2,711 2,819 2,453 2,099 1,932 1,875 1,950
Revenues from customers 94,068 96,955 94,878 90,840 87,983 93,545 89,487 88,647 84,944 83,523 80,958 80,490 76,658 76,237 73,548 72,327 68,800 69,306 66,852 65,157 66,593
Cost of products sold (51,057) (55,268) (52,948) (49,998) (48,073) (57,419) (54,688) (53,536) (51,455) (51,728) (50,365) (49,290) (45,509) (46,378) (45,011) (43,520) (40,894) (42,452) (40,940) (40,242) (40,347)
Health care costs (29,135) (29,543) (29,922) (27,853) (27,803) (22,518) (21,499) (21,782) (20,448) (18,305) (17,419) (17,606) (17,951) (16,574) (16,081) (15,901) (15,704) (15,145) (14,396) (11,751) (14,387)
Cost of revenues (80,192) (84,811) (82,870) (77,851) (75,876) (79,937) (76,187) (75,318) (71,903) (70,033) (67,784) (66,896) (63,460) (62,952) (61,092) (59,421) (56,598) (57,597) (55,336) (51,993) (54,734)
Gross profit 13,876 12,144 12,008 12,989 12,107 13,608 13,300 13,329 13,041 13,490 13,174 13,594 13,198 13,285 12,456 12,906 12,202 11,709 11,516 13,164 11,859
Net investment income 520 755 550 394 454 268 277 274 334 323 201 146 168 367 246 289 297 248 204 184 162
Operating expenses (11,022) (10,421) (10,557) (10,338) (10,290) (10,503) (9,876) (9,873) (9,580) (9,559) (9,606) (9,171) (9,876) (10,065) (9,210) (8,869) (8,922) (9,433) (8,471) (8,668) (8,563)
Restructuring charges (10) (1,169) (11) (496)
Opioid litigation charges (100) (583) (5,220)
Loss on assets held for sale (349) (53) (2,480)
Store impairments (1,358)
Goodwill impairment (431)
Operating income (loss) 3,374 2,368 832 3,045 2,271 3,373 3,690 3,234 3,446 3,618 (3,931) 4,569 3,490 2,229 3,061 4,326 3,577 2,524 3,249 4,680 3,458
Interest expense (785) (758) (752) (732) (716) (690) (693) (686) (589) (552) (566) (583) (586) (608) (602) (636) (657) (678) (731) (765) (733)
Gain (loss) on early extinguishment of debt 491 (89) (363) (674) (766)
Other income 28 25 25 24 25 22 22 22 22 43 41 43 42 38 49 45 50 53 54 45 54
Income (loss) before income tax (provision) benefit 2,617 2,126 105 2,337 1,580 2,705 3,019 2,570 2,879 3,109 (4,456) 4,029 2,946 1,570 2,145 3,735 2,970 1,225 1,806 3,960 2,779
Income tax (provision) benefit (835) (503) (34) (569) (456) (658) (754) (656) (737) (809) 1,047 (1,068) (633) (274) (558) (944) (746) (241) (587) (974) (767)
Income (loss) from continuing operations 1,782 1,623 71 1,768 1,124 2,047 2,265 1,914 2,142 2,300 (3,409) 2,961 2,313 1,296 1,587 2,791 2,224 984 1,219 2,986 2,012
Loss from discontinued operations, net of tax (9)
Net income (loss) 1,782 1,623 71 1,768 1,124 2,047 2,265 1,914 2,142 2,300 (3,409) 2,961 2,313 1,296 1,587 2,791 2,224 975 1,219 2,986 2,012
Net (income) loss attributable to noncontrolling interests (3) 21 16 2 (11) (1) (4) (13) (6) 2 (7) (10) (1) 10 11 (8) (1) (2) 5 (11) (5)
Net income (loss) attributable to CVS Health 1,779 1,644 87 1,770 1,113 2,046 2,261 1,901 2,136 2,302 (3,416) 2,951 2,312 1,306 1,598 2,783 2,223 973 1,224 2,975 2,007

Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

Revenues
The total revenues generally demonstrate a growing trend across the quarters, starting from approximately $66.6 billion in March 2020 and rising to around $94 billion by March 2025. This increase is primarily driven by the growth in both products and premiums categories. Product revenues show a steady progression with minor fluctuations, peaking at $65.2 billion in December 2023 before experiencing some declines. Premium revenues notably increase, especially from March 2023 onward, reaching $32.8 billion in March 2025.
Service revenues show more volatility, with increases noted in mid-2021 and sustained elevated levels through 2024 before a decrease in early 2025.
Cost of Revenues and Related Costs
Costs associated with products sold, health care, and overall revenues reveal an upward trajectory correlated with revenue growth. The cost of products sold rises from approximately $40.3 billion in March 2020 to peaks above $57 billion in late 2023 before a decline toward $51 billion by early 2025. Health care costs likewise increase substantially over the period, peaking near $29 billion in 2024, reflecting intensified expenditures in this segment.
Total cost of revenues follows a similar increasing pattern, reaching close to $85 billion in late 2024, before dropping slightly to around $80 billion by March 2025.
Profitability
Gross profit fluctuates but remains relatively stable around $12-13 billion per quarter with minor decreases in some quarters within 2024, specifically showing lower figures compared to the peak in December 2023. Operating income demonstrates significant variability, including negative spikes such as the large loss of approximately $3.9 billion in the third quarter of 2022, likely driven by exceptional charges or impairments within that period.
Despite fluctuations, operating income generally rebounds to positive territory, though with smaller margins compared to earlier years. Income before tax follows a similar pattern, showing considerable volatility with notable losses and recoveries.
Operating Expenses and Special Charges
Operating expenses remain consistent at levels around $8.5 to $10.5 billion each quarter, with some increases noted toward 2024 and 2025. Several one-time or irregular charges are observed, including restructuring charges commencing around late 2022, opioid litigation charges peaking notably in the third quarter of 2022, store impairments in late 2020 and early 2021, and goodwill impairment in 2021. These charges contribute to the negative impacts on operating income and fluctuations in financial performance.
Net Income and Taxation
Net income mirrors the trends observed in operating income, with overall growth from early 2020 figures around $2 billion, reaching highs near $2.9 billion in early 2022. The loss in late 2022 corresponds to the negative net income of approximately $3.4 billion. Subsequently, net income recovers, although the magnitude is slightly less robust in 2024 and early 2025. Income tax provision varies, with periods of benefit and higher taxation, reflecting the volatility in pre-tax incomes.
Other Financial Items
Net investment income remains relatively small but positive, showing some increases over time. Interest expense stays fairly stable, slightly increasing from about $733 million in early 2020 to approximately $785 million by early 2025. Gains and losses on early extinguishment of debt reveal occasional impacts on net income, with a notable gain recorded in the first quarter of 2025.
Summary
The data reflects a general growth trajectory in revenues, particularly in products and premiums, accompanied by increasing costs. The company experiences significant operational challenges in 2022 due to litigation and impairment charges, leading to a substantial negative impact on profitability in that period. However, profitability recovers afterward but does not consistently reach earlier peak levels. Operating expenses are stable with occasional infrequent charges influencing quarterly results. Tax expenses vary in correlation with income fluctuations, and interest costs remain stable. Overall, the financial data highlights resilience amid challenges and steady top-line growth.